Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque
Among the vaccines have been developed thus far against SARS-CoV-2, the mRNA-based ones have demonstrated more promising results regarding both safety and efficacy. Two remarkable features of the mRNA vaccines introduced by the Pfizer/BioNTech and Moderna companies are the use of (N<sup>1</...
Main Authors: | Alireza Naderi Sohi, Jafar Kiani, Ehsan Arefian, Arezou Khosrojerdi, Zahra Fekrirad, Shokoofeh Ghaemi, Mohammad Kazem Zim, Arsalan Jalili, Nazila Bostanshirin, Masoud Soleimani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/9/1007 |
Similar Items
-
Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
by: Javier T. Granados-Riveron, et al.
Published: (2021-10-01) -
Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety
by: Irena Vlatkovic
Published: (2021-05-01) -
Impact of Ribosome Activity on SARS-CoV-2 LNP – Based mRNA Vaccines
by: Evangelos Tsiambas, et al.
Published: (2021-04-01) -
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
by: Matthew Behr, et al.
Published: (2021-08-01) -
Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands
by: Zubao Gan, et al.
Published: (2020-09-01)